Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

Effect of Pentoxifylline on Recurrence in Patients With Multiple Sclerosis: A Non-Randomized Double-Blinded Placebo Controlled Clinical Trial

Akbar Hamzei Moghaddam 1 , Rostam Seiffaddini 1 , Asma Najafzadeh 1 , * , Hossien Ali Ghaffaripour 2 , Peyman Arasteh 3 , Zeinab Movahhedi 4 and Narges Khanjani 1
Authors Information
1 Department of Neurology, Neurology Research Center, Kerman University of Medical Sciences, Kerman, IR Iran
2 Pediatric Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Students Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 PhD Student of Nursing, Department of Nursing, Kerman University of Medical Sciences, Kerman, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: November 28, 2015, 17 (11); e2227
  • Published Online: November 1, 2015
  • Article Type: Research Article
  • Received: April 16, 2014
  • Accepted: June 10, 2014
  • DOI: 10.17795/zjrms-2227

To Cite: Hamzei Moghaddam A, Seiffaddini R, Najafzadeh A, Ghaffaripour H A, Arasteh P, et al. Effect of Pentoxifylline on Recurrence in Patients With Multiple Sclerosis: A Non-Randomized Double-Blinded Placebo Controlled Clinical Trial, Zahedan J Res Med Sci. 2015 ; 17(11):e2227. doi: 10.17795/zjrms-2227.

Abstract
Copyright © 2015, Zahedan University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Lublin FD, Miller AE. Neurology in clinical practice. 2008; : 1583-608
  • 2. Riley CS, Tullman MJ. Merritt's neurology. 2010; : 904-7
  • 3. Ropper AH, Samuels MA. Adams & Victor's Principles of Neurology. 2009; : 874-95
  • 4. van Oosten BW, Rep MH, van Lier RA, Scholten PE, von Blomberg BM, Pflughaupt KW, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol. 1996; 66(1-2): 49-55[PubMed]
  • 5. Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol. 1992; 40(2-3): 211-8[PubMed]
  • 6. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988; 23(4): 339-46[DOI][PubMed]
  • 7. Puccioni-Sohler M, Rieckmann P, Kitze B, Lange P, Albrecht M, Felgenhauer K. A soluble form of tumour necrosis factor receptor in cerebrospinal fluid and serum of HTLV-I-associated myelopathy and other neurological diseases. J Neurol. 1995; 242(4): 239-42[PubMed]
  • 8. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand. 1988; 78(4): 318-23[PubMed]
  • 9. Wang X, Ma C, Wu J, Zhu J. Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models. J Neurosci Res. 2013; 91(7): 871-81[DOI][PubMed]
  • 10. Tumani H, Kassubek J, Hijazi M, Lehmensiek V, Unrath A, Sussmuth S, et al. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur Neurol. 2011; 65(3): 164-9[DOI][PubMed]
  • 11. Awad AM, Stuve O. Immunopathogenesis of multiple sclerosis: new insights and therapeutic implications. Continuum (Minneap Minn). 2010; 16(5 Multiple Sclerosis): 166-80[DOI][PubMed]
  • 12. Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 1996; 64(2): 193-200[PubMed]
  • 13. All about multiple sclerosis: MS news and information on diagnosis, symptoms, and treatments. 2011;
  • 14. Bisaga GN, Odinak MM, Boiko AN, Mel'nik Iu B, Popova NF. [Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy]. Zh Nevrol Psikhiatr Im S S Korsakova. 2011; 111(2): 44-8[PubMed]
  • 15. Weber F, Polak T, Gunther A, Kubuschok B, Janovskaja J, Bitsch A, et al. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol. 1998; 44(1): 27-34[DOI][PubMed]
  • 16. Jafarzadeh A, Ebrahimi HA, Bagherzadeh S, Zarkesh F, Iranmanesh F, Najafzadeh A, et al. Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women. Inflammation. 2014; 37(2): 604-10[DOI][PubMed]
  • 17. Pede PD, Visintini D, Telera A, Cucurachi L, Campanini C, Immovilli P, et al. Immunomodulatory effects of IFN-beta1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS). J Interferon Cytokine Res. 2005; 25(8): 485-9[DOI][PubMed]
  • 18. Odinak MM, Bisaga GN, Zarubina IV. [New approaches to antioxidant therapy in multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2002; : 72-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments